Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 2Retinoblastoma 1

Interventions

Irinotecan 31Paclitaxel 27Gemcitabine 27Cisplatin 25Docetaxel 20Oxaliplatin 16Fluorouracil 15alvocidib 13Leucovorin 13Carboplatin 13Capecitabine 12Bortezomib 10Early Intervention, Educational 9Topotecan 8Taxes 8Bevacizumab 73-aminopyridine-2-carboxaldehyde thiosemicarbazone 7ixabepilone 6Vorinostat 6Temozolomide 6Sorafenib 6Immunohistochemistry 6Immunoenzyme Techniques 67-hydroxystaurosporine 6tanespimycin 5Pharmacogenomic Testing 5Pemetrexed 5Magnetic Resonance Spectroscopy 5Filgrastim 5Etoposide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unspecified Adult Solid Tumor, Protocol Specific × trioctyl phosphine oxide × Other solid neoplasm × Clear all
NCT00541359 2017-08-09

Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

City of Hope Medical Center

Phase 1 Completed
54 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00068484 2013-02-01

A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies

National Cancer Institute (NCI)

Phase 1 Completed
25 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡